Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity

被引:792
作者
Roxburgh, RHSR
Seaman, SR
Masterman, T
Hensiek, AE
Sawcer, SJ
Vukusic, S
Achiti, I
Confavreux, C
Coustans, M
le Page, E
Edan, G
McDonnell, GV
Hawkins, S
Trojano, M
Liguori, M
Cocco, E
Marrosu, MG
Tesser, F
Leone, MA
Weber, A
Zipp, F
Miterski, B
Epplen, JT
Oturai, A
Sorensen, PS
Celius, EG
Lara, NT
Montalban, X
Villoslada, P
Silva, AM
Marta, M
Leite, I
Dubois, B
Rubio, J
Butzkueven, H
Kilpatrick, T
Mycko, MP
Selmaj, KW
Rio, ME
Sá, M
Salemi, G
Savettieri, G
Hillert, J
Compston, DAS
机构
[1] Univ Cambridge, Dept Neurol, Cambridge CB2 2QQ, England
[2] Auckland City Hosp, Auckland, New Zealand
[3] Max Planck Inst Psychiat, D-80804 Munich, Germany
[4] Huddinge Univ Hosp, Karolinska Inst, NEUROTEC, Div Neurol, Stockholm, Sweden
[5] Hop Neurol, EDMUS Coordinating Ctr, Serv Neurol A, Lyon, France
[6] Univ Rennes, Hop Pontchaillou, Ctr Hosp, Rennes, France
[7] Royal Victoria Hosp, No Ireland Reg Neurol Serv, Belfast BT12 6BA, Antrim, North Ireland
[8] Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy
[9] Multipla Univ Cagliari, Ctr Sclerosi, Dept Neurosci, Cagliari, Italy
[10] Univ Piemonte Orientale, Novara, Italy
[11] Osped Maggiore Car, Novara, Italy
[12] Univ Klinikum Charite, Neurowissenschaftlich Zentrum, Inst Neuroimmunol, Berlin, Germany
[13] Ruhr Univ Bochum, Abt Humangenet, D-4630 Bochum, Germany
[14] Copenhagen Univ Hosp, Dept Neurol, Rigshosp, Copenhagen, Denmark
[15] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway
[16] Univ Hosp, Clin Neuroimmunol Unit, Barcelona, Spain
[17] Univ Navarra Clin, Dept Neurol, Multiple Sclerosis Ctr, Navarra, Spain
[18] Hosp Geral Santo Antonio, Dept Neurol, Neuroimmunol Grp, Oporto, Portugal
[19] Univ Louvain, Univ Hosp Gasthuisberg, Louvain, Belgium
[20] Walter & Eliza Hall Inst Med Res, IG Royal Parade, Parkville, Vic, Australia
[21] Cooperat Res Ctr Drug Discovery Genes Common Huma, Richmond, Vic, Australia
[22] Med Univ Lodz, Dept Neurol, Lodz, Poland
[23] Hosp Sao Joao, Dept Neurol, Oporto, Portugal
[24] Dept Neuropsichiat, Palermo, Italy
关键词
D O I
10.1212/01.WNL.0000156155.19270.F8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.
引用
收藏
页码:1144 / 1151
页数:8
相关论文
共 13 条
[1]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[2]  
Fisher LD, 1993, BIOSTATISTICS
[3]   The Multiple Sclerosis Impact Scale (MSIS-29) - A new patient-based outcome measure [J].
Hobart, J ;
Lamping, D ;
Fitzpatrick, R ;
Riazi, A ;
Thompson, A .
BRAIN, 2001, 124 :962-973
[4]   Identifying disease modifying genes in multiple sclerosis [J].
Kantarci, OH ;
de Andrade, M ;
Weinshenker, BG .
JOURNAL OF NEUROIMMUNOLOGY, 2002, 123 (1-2) :144-159
[5]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[6]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231
[7]   A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility [J].
Sawcer, S ;
Maranian, M ;
Setakis, E ;
Curwen, V ;
Akesson, E ;
Hensiek, A ;
Coraddu, F ;
Roxburgh, R ;
Sawcer, D ;
Gray, J ;
Deans, J ;
Goodfellow, PN ;
Walker, N ;
Clayton, D ;
Compston, A .
BRAIN, 2002, 125 :1337-1347
[8]   STRATIFIED OR MULTICENTER ANALYSIS WITH EXTENDED MANTEL-HAENSZEL STATISTICS [J].
SCHINDEL, F ;
KWASNY, H .
BIOMETRICAL JOURNAL, 1991, 33 (06) :755-762
[9]   Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis [J].
Schmidt, S ;
Barcellos, LF ;
DeSombre, K ;
Rimmler, JB ;
Lincoln, RR ;
Bucher, P ;
Saunders, AM ;
Lai, E ;
Martin, ER ;
Vance, JM ;
Oksenberg, JR ;
Hauser, SL ;
Pericak-Vance, MA ;
Haines, JL .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 70 (03) :708-717
[10]   Age-related disability in multiple sclerosis [J].
Trojano, M ;
Liguori, M ;
Zimatore, GB ;
Bugarini, R ;
Avolio, C ;
Paolicelli, D ;
Giuliani, F ;
De Robertis, F ;
Marrosu, MG ;
Livrea, P .
ANNALS OF NEUROLOGY, 2002, 51 (04) :475-480